Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.01USD
24 Jul 2017
Change (% chg)

$-2.30 (-1.70%)
Prev Close
$135.31
Open
$134.99
Day's High
$135.02
Day's Low
$132.86
Volume
2,656,033
Avg. Vol
1,927,191
52-wk High
$137.07
52-wk Low
$109.32

Select another date:

Mon, Jul 24 2017

US STOCKS SNAPSHOT-J&J weighs on Dow, S&P; Nasdaq hits record

NEW YORK, July 24 The Nasdaq hit a record high on Monday ahead of a big week of technology earnings reports, while the S&P 500 and the Dow industrials lagged behind as losses in healthcare heavyweight Johnson & Johnson took a toll.

UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative

NEW YORK/SEOUL, July 24 Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine.

US STOCKS-S&P, Dow lower as Johnson & Johnson drags

* Indexes down: Dow 0.32 pct, S&P 0.21 pct, Nasdaq 0.03 pct (Adds details, changes comment, updates prices)

BRIEF-EU Medicines Agency recommends approval J&J unit's Symtuza drug for HIV

* EU Medicines Agency recommends approval of Johnson & Johnson unit Janssen-Cilag International N.V. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) drug for HIV Source text ID: (http://bit.ly/2vIbPPG) Further company coverage:

UPDATE 2-China adds blockbuster drugs to insurance list after price cuts

* Gov't, drugmakers agreed price cuts of as much as 70 pct (Adds picture)

J&J sees sales growth in near-term; raises 2017 profit forecast

Johnson & Johnson said it expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as cancer drugs Darzalex and Imbruvica.

UPDATE 5-J&J sees sales growth in near-term; raises 2017 profit forecast

* Pharmaceutical sales miss estimates for third straight qtr -RBC

CORRECTED-UPDATE 4-J&J sees sales growth in near-term; raises 2017 profit forecast

* Pharmaceutical sales miss estimates for third straight qtr - RBC

J&J reports dip in quarterly profit

July 18 Johnson & Johnson, which completed its $30 billion acquisition of Swiss biotech Actelion last month, reported a 4.3 percent fall in quarterly profit, as costs rose.

BRIEF-J&J sets quarterly cash dividend of $0.84 per share

* Sets quarterly cash dividend of $0.84 per share Source text for Eikon: Further company coverage:

Select another date: